COVID-19 recommended schedule for the general population:

| Age | Product | Primary Series | Booster dose? * |
|--------------|-----------------------------|--------------------------------|---------------------|
| 5 – 11 years | Pfizer (orange cap) | 2 doses: 21 days apart | None |
| 12-17 years | Pfizer (purple or gray cap) | 2 doses: 21 days apart | 5 months after dose |
| | | | 2 |
| 18 years and | Pfizer (purple or gray cap) | 2 doses: 21 days apart | 5 months after dose |
| older | | | 2 |
| 18 years or | Moderna | 2 doses: 28 days apart (0.5mL) | 5 months after dose |
| older | | | 2 (0.25 mL) |
| 18 years or | Janssen (J&J) | One dose | 2 months later |
| older | | | |

COVID-19 recommended schedule for people with moderate to severe immunocompromise:

| Age | Product | Primary Series | Booster dose? * |
|--------------------|-----------------------------|---|-----------------------|
| 5 – 11 years | Pfizer (orange cap) | 3 doses: Dose 1 to 2 - 21 days, Dose 2 to 3 - 28 days | None |
| 12 – 17 years | Pfizer (purple or gray cap) | 3 doses: Dose 1 to 2 - 21 days, Dose 2 to 3 - 28 days | 5 months after dose 3 |
| 18 years and older | Pfizer (purple or gray cap) | 3 doses: Dose 1 to 2 - 21 days, Dose 2 to 3 - 28 days | 5 months after dose 3 |
| 18 years or older | Moderna | 3 doses: Dose 1 to 2 - 28 days, Dose 2 to 3 - 28 days Dose#3 (0.5 mL) | 5 months after dose 3 |
| 18 years or older | Janssen (J&J) | one dose | 2 months later |

^{*} CDC recommends use of the same brand for each dose in the primary series. Any age-appropriate option may be used as the booster dose; mRNA vaccines are preferred.

FDA: EUA Fact Sheets, dates of current versions:

| Product | For Healthcare Providers | For Recipients |
|---|--------------------------|-----------------|
| Pfizer-BioNTech, 5 through 11 y, orange cap | 03 January 2022 | 03 January 2022 |
| Pfizer-BioNTech, 12+ y, purple cap | 03 January 2022 | 03 January 2022 |
| Pfizer-BioNTech, 12+ y, gray cap | 03 January 2022 | 03 January 2022 |
| Moderna | 31 January 2022 | 31 January 2022 |
| Janssen (J&J) | 31 January 2022 | 31 January 2022 |

CDC Emergency Use Instructions (EUI) for use of Pfizer-BioNTech mRNA vaccine in people given vaccines not authorized in the United States:

• For Healthcare Providers: **07 January 2022**

• For Recipients: **07 January 2022**

Source of material:

• <u>www.lmmunize.org</u>

• Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC